Medipal Holdings is a Tokyo-based holding company established in 1898, specializing in the distribution of pharmaceuticals, cosmetics, and daily necessities. The company operates through three main segments: prescription pharmaceuticals, cosmetics and over-the-counter (OTC) products, and animal health products. The prescription pharmaceutical segment is the largest revenue generator, supplying hospitals, clinics, and pharmacies with essential medications. The cosmetics and OTC pharmaceutical segments cater to drugstores, convenience stores, and supermarkets, providing a wide range of health and beauty products. Additionally, the animal health segment serves veterinary hospitals and agricultural needs, ensuring a comprehensive approach to health and wellness across various markets.
Presus Cube is a business specializing in pharmacy management support services. It offers data discovery, standardizing pharmacy operations, and survey support to assist clients in informed decision-making and policy creation.
Heartseed
Series C in 2021
Heartseed Inc., founded in 2015 and located in Tokyo, Japan, focuses on developing myocardial regeneration medicine using induced pluripotent stem (iPS) cells. The company is dedicated to advancing the clinical application of regenerative medicine for heart disease, specifically through the development and commercialization of iPS cell-derived cardiomyocyte replacement therapy aimed at treating advanced heart failure. Heartseed's mission is to transform heart disease treatment by pioneering innovative solutions in myocardial regeneration.
Heartseed
Corporate Round in 2020
Heartseed Inc., founded in 2015 and located in Tokyo, Japan, focuses on developing myocardial regeneration medicine using induced pluripotent stem (iPS) cells. The company is dedicated to advancing the clinical application of regenerative medicine for heart disease, specifically through the development and commercialization of iPS cell-derived cardiomyocyte replacement therapy aimed at treating advanced heart failure. Heartseed's mission is to transform heart disease treatment by pioneering innovative solutions in myocardial regeneration.
FunPep
Venture Round in 2018
FunPep is a biotechnology company dedicated to the research and development of pharmaceuticals, cosmetics, and medical devices centered on functional peptides. The company specializes in creating treatments for intractable peptic ulcer disease, including antibody drugs and other pharmaceutical products. FunPep aims to innovate within the pharmaceutical sector by replacing traditional antibody medicines with next-generation products that utilize antibody-inducing peptides. Through its diverse portfolio, FunPep seeks to advance healthcare solutions and improve patient outcomes.
Clipla
Venture Round in 2018
CLIPLA specializes in providing cloud-based electronic medical records and healthcare services tailored for hospitals. The company's offerings encompass a wide range of products designed for various departments, facilitating efficient data capture and storage. By minimizing installation and maintenance costs, CLIPLA enables healthcare facilities to streamline operations, thereby reducing the workload of staff members, including doctors, nurses, and clerical personnel. This approach fosters a more comfortable and efficient medical treatment workflow.
Scohia Pharma
Venture Round in 2017
Scohia Pharma, Inc. is a biotechnology company based in Fujisawa, Japan, that specializes in researching, designing, and developing therapeutic drugs for metabolic, cardiovascular, and renal diseases. Established in 2017, the company focuses on addressing conditions such as obesity, diabetes, dyslipidemia, and hypertension through its innovative pipeline of drug development programs. Scohia Pharma aims to enhance patient quality of life by providing new treatment options for patients and healthcare professionals, leveraging its substantial research and development capabilities while maintaining the agility to make swift decisions in the evolving pharmaceutical landscape.
FunPep
Venture Round in 2016
FunPep is a biotechnology company dedicated to the research and development of pharmaceuticals, cosmetics, and medical devices centered on functional peptides. The company specializes in creating treatments for intractable peptic ulcer disease, including antibody drugs and other pharmaceutical products. FunPep aims to innovate within the pharmaceutical sector by replacing traditional antibody medicines with next-generation products that utilize antibody-inducing peptides. Through its diverse portfolio, FunPep seeks to advance healthcare solutions and improve patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.